Amgen nhasi akazivisa kuratidzwa kwekuita uye kuchengetedza data kubva kuCodeBreaK 100 Phase 1/2 kuyedzwa muvarwere vane KRAS G12C-yakagadziriswa advanced pancreatic cancer vakagamuchira LUMAKRAS® (sotorasib). Iyo data ichaunzwa pamwedzi weAmerican Society of Clinical Oncology (ASCO) Plenary Series musi waKukadzi 15, 2022. Dhata inoratidza inokurudzira uye yekiriniki ine chinangwa chekurwisa kenza uye bhenefiti yakanaka: nhoroondo yenjodzi.
"Kubva pane idzi data dzinonakidza, tiri kuwedzera CodeBreaK 100 kunyoresa varwere vakawanda vane pancreatic nedzimwe mhando dzebundu kuti vanzwisise zviri nani kushanda uye kuchengetedzeka kweLUMAKRAS mumamota kunze kweasiri madiki sero remapapu uye colorectal cancer," akadaro David M. Reese. , MD, mutevedzeri wemutevedzeri wemutungamiri weKutsvagisa neBudiriro kuAmgen. "CodeBreaK ndiyo yakakura uye yakatambanuka pasi rose chirongwa chekuyedza kiriniki kusvika parizvino ine imwe yakasimba, yakaongororwa nepakati dataset. Sezvo isu tichidzidza zvakawanda kubva kune yakakura data yatinounganidza, isu ticharamba tichiisa mari muchirongwa nekuwedzera macohorts uye kuongorora misanganiswa mitsva kuitira kuti tigone kubatsira varwere vazhinji sezvinobvira. "
LUMAKRAS yakaratidza chepakati chakasimbiswa chinangwa chekupindura mwero (ORR) we21% uye chirwere chekudzora mwero (DCR) che84% pamakumi matatu nemasere akarapwa zvakanyanya akafanorapwa cancer cancer varwere. Vanosvika 38% yevarwere vakagamuchira LUMAKRAS semutsetse wechitatu kana kuti gare gare kurapwa. Vasere vevarwere ve80 vakawana mhinduro yakasimbiswa (PR) yakaitwa neakapofumadzwa akazvimirira central review (BICR). Vaviri vevarwere vasere vane PR vane mhinduro dziripo. Nguva yeMedian yekupindura yaive mwedzi 38 nekutevera kwepakati kwemwedzi ye5.7 kubva pazuva rekucheka data raNov. OS) yeinenge mwedzi 16.8. Hapana masaini matsva ekuchengetedza akaonekwa neongororo iyi yevarwere vane advanced pancreatic cancers. Zviitiko zvakashata zvine chekuita nekurapa (TRAEs) yegiredhi chero ripi zvaro zvakaitika mu1 (2021%) varwere vane manyoka (4%) uye kuneta (7%) seyakajairika giredhi 16 TRAEs. Hapana maTRAE aiuraya kana kuti akaguma nekurega kurapwa.
"Mushure memakumi emakore ekutsvagisa, marapirwo aripo evarwere vane cancer yepancreatic anopa rubatsiro rushoma rwekupona, zvichiratidza kukosha kwakakosha kweinoveli, yakachengeteka uye inoshanda nzira dzekurapa," akadaro John Strickler, MD akabatana purofesa wemishonga, Duke University Chikoro cheMishonga uye gastrointestinal oncologist. . "Mune dataset yakakura kwazvo inoongorora kushanda uye kuchengetedzeka kweKRASG12C inhibitor muchirwere chegomarara repancreatic, sotorasib yakawana mhinduro yakasimbiswa ye21% uye chiyero chekudzora chirwere che84%. Izvi zvine zvazvinoreva kuvarwere nekuti hapana marapirwo akatemerwa evarwere ava kana vangosvika padanho rechitatu rekurapwa."
Gomarara repancreas chirwere chinouraya zvakanyanya. Ndiyo yechina inotungamira kufa kwegomarara mune vese varume nevakadzi muUS vane makore mashanu ekupona kweanosvika gumi muzana muzana. Pane kudiwa kwakanyanya kusingakwane kwevarwere vane gomarara repancreatic rakaenderera mberi mushure mekurapwa kwemutsara wekutanga, uko FDA-yakatenderwa mutsara wepiri kurapa yakapa kupona kwemwedzi ingangoita mitanhatu uye chiyero chekupindura che5%. Mushure mekufambira mberi pane yekutanga-uye yechipiri-mutsara chemotherapy, hapana marapirwo ane anoratidzwa kupona kubatsirwa. Pasinei nekufambira mberi mukurapa, zvishoma kuvandudzwa kwakaitwa kuvandudza kuongororwa uye kurapwa kwepancreatic cancer.
Zvinofungidzirwa kuti vangangosvika makumi mapfumbamwe muzana evarwere vane pancreatic cancer vanobata KRAS mutation ine KRAS G90C inoverengera ingangoita 12-1% yekuchinja uku.
ZVOKUBVA MUNYAYA INO:
- “In the largest dataset evaluating the efficacy and safety of a KRASG12C inhibitor in heavily pretreated advanced pancreatic cancer, sotorasib achieved a centrally confirmed response rate of 21% and a disease control rate of 84%.
- “Based on these exciting data, we are expanding CodeBreaK 100 to enroll more patients with pancreatic and other tumor types to better understand the efficacy and safety of LUMAKRAS in tumors outside of non-small cell lung and colorectal cancers,”.
- There is a high unmet need for patients with advanced pancreatic cancer that has progressed after first-line treatment, where FDA-approved second-line therapy has provided survival of about six months and a response rate of 16%.
